| abstract |
the present invention relates to solid, orally administrable pharmaceutical administration forms comprising 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide (rivaroxaban, active ingredient (I)), characterized in that a portion of the active ingredient (I) is released in a rapid manner and a portion in a controlled (modified, retarded, delayed) manner, and to processes for production thereof, use thereof as medicaments, and use thereof for prophylaxis, secondary prophylaxis or treatment of disorders. |